Back to search
FDAFDA · Food and drugs·Recall number D-0369-2022

8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL), 50 mL vials, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC., Lenoir, NC 28645, NDC 51754-5001-1

Published January 19, 2022 · Recall initiated: January 11, 2022

Summary

FDA records drug Class II recall D-0369-2022, published January 19, 2022 and initiated January 11, 2022. Recalling firm: Exela Pharma Sciences LLC; Status: Terminated; Reported quantity: 18,960 vials; Lot: Lot #: C0001088/P0001317, Exp. Date 08/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Exela Pharma Sciences LLC
Distributor
Nationwide within the United States
Lot
Lot #: C0001088/P0001317, Exp. Date 08/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was 8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL), 50 mL vials, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC., Lenoir, NC 28645, NDC 51754-5001-1 recalled?

Yes. FDA published recall D-0369-2022 on January 19, 2022. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter